Pharmacology

Articles:

169 Diversity-oriented synthesis yields novel multistage antimalarial inhibitors.
http://www.nature.com/nature/journal/v538/n7625/full/nature19804.html

168 Purinergic receptors in the carotid body as a new drug target for controlling hypertension.
http://www.nature.com/nm/journal/v22/n10/abs/nm.4173.html

167 Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO).
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)31324-1/fulltext

166 Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA).
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)31322-8/fulltext

165 Fragment-based discovery of a new family of non-peptidic small-molecule cyclophilin inhibitors with potent antiviral activities.
http://www.nature.com/articles/ncomms12777

164 Treatment of otitis media by transtympanic delivery of antibiotics.
http://stm.sciencemag.org/content/8/356/356ra120

163 A selective inhibitor of the kinetoplastid proteasome (GNF6702) is identified that is highly efficacious in vivo, clearing the parasites that cause leishmaniasis, Chagas disease and sleeping sickness from mice, highlighting the possibility of developing a single class of drugs for these neglected diseases.
http://www.nature.com/nature/journal/v537/n7619/full/nature19339.html

162 Like citrate, the molecule hydroxycitrate is shown to inhibit growth of the crystal that is the principal component of kidney stones, suggesting that hydroxycitrate could be another treatment for kidney stone disease.
http://www.nature.com/nature/journal/v536/n7617/full/nature19062.html

161 Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors.
http://www.nature.com/ncomms/2016/160801/ncomms12348/full/ncomms12348.html

160 Novel cell-free high-throughput screening method for pharmacological tools targeting K+ channels.
http://www.pnas.org/content/113/20/5748

159 Soluble guanylate cyclase as an alternative target for bronchodilator therapy in asthma.
http://www.pnas.org/content/113/17/E2355.abstract

158 Oral activity of a nature-derived cyclic peptide for the treatment of multiple sclerosis.
http://www.pnas.org/content/113/15/3960.abstract

157 On-demand continuous-flow production of pharmaceuticals in a compact, reconfigurable system.
http://science.sciencemag.org/content/352/6281/61

156 Precision multidimensional assay for high-throughput microRNA drug discovery.
http://www.nature.com/ncomms/2016/160216/ncomms10709/full/ncomms10709.html

155 Discovery of cahuitamycins as biofilm inhibitors derived from a convergent biosynthetic pathway.
http://www.nature.com/ncomms/2016/160216/ncomms10710/full/ncomms10710.html

154 Long-acting cocaine hydrolase for addiction therapy.
http://www.pnas.org/content/113/2/422.abstract

153 BRD4 is a novel therapeutic target for liver fibrosis.
http://www.pnas.org/content/112/51/15713.abstract

152 Implantable synthetic cytokine converter cells with AND-gate logic treat experimental psoriasis.
http://stm.sciencemag.org/content/7/318/318ra201

151 Structural studies give insight into how a human sodium channel involved in pain perception can be selectively inhibited.
http://www.sciencemag.org/content/350/6267/aac5464.abstract

150 Yeast-based screening identifies the benzodiazepine drug lorazepam as a non-selective positive allosteric modulator of the G-protein-coupled receptor (GPCR) GPR68; homology modelling and molecular docking of 3.1 million molecules found a new compound, ‘ogerin’, as a potent GPR68 modulator, which suppressed recall in fear conditioning in wild-type mice, and the general method of combining physical and structure-based screening may lead to the discovery of selective ligands for other GPCRs.
http://www.nature.com/nature/journal/v527/n7579/full/nature15699.html

Free Images for Presentation: sunipix SUNIPIX